相似文献
1
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.
Breast Care (Basel). 2022 Aug;17(4):403-420. doi: 10.1159/000524879. Epub 2022 May 5.
2
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.
Breast Care (Basel). 2023 Aug;18(4):289-305. doi: 10.1159/000531578. Epub 2023 Jun 16.
3
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
Breast Care (Basel). 2024 Jun;19(3):165-182. doi: 10.1159/000538596. Epub 2024 Apr 18.
4
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.
Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30.
5
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
Breast Care (Basel). 2024 Jun;19(3):183-191. doi: 10.1159/000538753. Epub 2024 Apr 10.
6
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
Breast Care (Basel). 2022 Aug;17(4):421-429. doi: 10.1159/000524789. Epub 2022 May 2.
7
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023.
Breast Care (Basel). 2023 Aug;18(4):306-315. doi: 10.1159/000531579. Epub 2023 Jun 16.
8
German Recommendations for Diagnosis and Treatment of Breast Cancer 2008. What is New from the Breast Commission of the German Gynaecological Oncology Working Group (AGO)?
Breast Care (Basel). 2008;3(2):93-99. doi: 10.1159/000127441. Epub 2008 May 15.
9
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.
Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):181-205. doi: 10.1055/a-1671-2446. eCollection 2022 Feb.
10
Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations.
Geburtshilfe Frauenheilkd. 2023 Sep 12;83(9):1102-1116. doi: 10.1055/a-2121-2495. eCollection 2023 Sep.
引用本文的文献
1
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis.
Breast Cancer Res Treat. 2025 Aug 13. doi: 10.1007/s10549-025-07778-4.
2
Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?
Geburtshilfe Frauenheilkd. 2025 Apr 22;85(6):590-598. doi: 10.1055/a-2562-8469. eCollection 2025 Jun.
3
Oncological outcomes of breast cancer patients after planned IORT boost with low-kV x-rays-results of the TARGIT BQR prospective phase IV trial.
Strahlenther Onkol. 2025 May 19. doi: 10.1007/s00066-025-02412-0.
4
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.
Geburtshilfe Frauenheilkd. 2025 May 15;85(5):493-506. doi: 10.1055/a-2533-2783. eCollection 2025 May.
5
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?
Breast Care (Basel). 2025 Mar 13:1-9. doi: 10.1159/000544906.
6
Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine.
Arch Gynecol Obstet. 2025 Jun;311(6):1683-1695. doi: 10.1007/s00404-025-08002-w. Epub 2025 Apr 9.
7
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Breast. 2025 Jun;81:104458. doi: 10.1016/j.breast.2025.104458. Epub 2025 Mar 22.
8
Navigating the Uncertainty of B3 Breast Lesions: Diagnostic Challenges and Evolving Management Strategies.
J Pers Med. 2025 Jan 18;15(1):36. doi: 10.3390/jpm15010036.
9
Comparative assessment of breast volume using a smartphone device versus MRI.
Breast Cancer. 2025 Jan;32(1):166-176. doi: 10.1007/s12282-024-01647-6. Epub 2024 Nov 15.
10
Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.
ESMO Open. 2024 Nov;9(11):103963. doi: 10.1016/j.esmoop.2024.103963. Epub 2024 Oct 26.
本文引用的文献
1
Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis.
Cancer Biol Med. 2022 Feb 16;19(5):742-54. doi: 10.20892/j.issn.2095-3941.2021.0529.
2
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
3
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Lancet Oncol. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3.
4
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Ann Oncol. 2022 Apr;33(4):384-394. doi: 10.1016/j.annonc.2022.01.009. Epub 2022 Jan 31.
5
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18.
6
Ductal Carcinoma in Situ: State-of-the-Art Review.
Radiology. 2022 Feb;302(2):246-255. doi: 10.1148/radiol.211839. Epub 2021 Dec 21.
7
Contrast-enhanced Mammography: A Systematic Review and Meta-Analysis of Diagnostic Performance.
Radiology. 2022 Mar;302(3):568-581. doi: 10.1148/radiol.211412. Epub 2021 Dec 14.
8
Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS).
Cancers (Basel). 2021 Dec 3;13(23):6103. doi: 10.3390/cancers13236103.
9
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7.
10
Contralateral breast cancer after curative-intent treatment for ductal carcinoma in situ: Rate and associated clinicopathological and imaging risk factors.
Clin Imaging. 2022 Feb;82:179-192. doi: 10.1016/j.clinimag.2021.11.018. Epub 2021 Nov 20.
Zotero 插件